Lv2
174 积分 2021-03-05 加入
Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies
2个月前
已完结
Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1
3个月前
已完结
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
4个月前
已完结
Lisaftoclax (APG-2575) is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
6个月前
已完结
Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy
6个月前
已完结
Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells
6个月前
已完结
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
8个月前
已完结
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
8个月前
已完结
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
8个月前
已完结
皖公网安备34019202002308
